News

Roche’s Enspryng Receives FDA Priority Review for Thyroid Eye Disease

Roche has announced that the US Food and Drug Administration (FDA) has accepted and granted priority review to a supplemental Biologics License Application (sBLA) for Enspryng (satralizumab) as a potential treatment for thyroid eye disease (TED). TED, also known as Graves’ ophthalmopathy, is a rare autoimmune inflammatory disease that affects the area around the eyes […]